Posters & Publications

Publications

American Heart Journal (Volume 165, Issue 2, February 2013)

• Spaced Administration of PA32540 and Clopidogrel Results in Greater Platelet Inhibition than Synchronous Administration of Enteric-coated Aspirin and Anteric-coated Omeprazole and Clopidogrel

Clinical Pharmacology & Therapeutics (Volume 90, Number 6, December 2011)

• Pharmacodynamic Evaluation of Clopidogrel Plus PA32540: The Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) Study

Posters

Academy of Managed Care Pharmacy (April 2013)

• Burden of Secondary Cardiovascular Disease in Commercial and Medicare Patients: A Managed Care Perspective

International Stroke Conference (February 2013)

• Combined Results of Two Phase 3 Studies of PA32540, an Antiplatelet Therapy of Enteric-Coated Aspirin and Immediate-Release Omeprazole, in Patients with Previous Cerebrovascular Disease

American Heart Association (November 2012)

• Treatment Continuation and Cardiovascular Safety of Antiplatelet Therapy with PA32540, A Tablet with Enteric-Coated Aspirin and Immediate-Release Omeprazole: Results of Two 6-Month, Phase 3 Studies

American College of Gastroenterology (October 2012)

• PA32540 (Enteric-Coated Aspirin 325 mg + Immediate-Release Omeprazole 40 mg) is Associated with Significantly Fewer Gastric Ulcers and Significantly Less Endoscopic Erosive Esophagitis than Enteric-Coated Aspirin (EC-ASA) Alone: Results of Two Phase 3 Studies

European Society of Cardiology – Munich, Germany (August 2012)

• Spaced Administration of PA32540 and Clopidogrel Results in Greater Platelet Inhibition Than Synchronous Administration of Enteric-Coated Aspirin and Enteric-Coated Omeprazole and Clopidogrel

The International Stroke Conference – New Orleans, LA (February 2012)

• Consumer Survey Indicates Aspirin Use Remains Less than Optimal in Stroke Survivors

The American Heart Association Scientific Sessions – Orlando, FL (November 2011)

• Platelet Inhibition with PA32540 (a Tablet of Enteric-Coated Aspirin and Immediate-Release Omeprazole ) + Clopidogrel Dosed Separately Is Greater Than Enteric-Coated Aspirin + Enteric-Coated Omeprazole + Clopidogrel Dosed Synchronously: Results of a Randomized, Open-Label, Cross-Over Study

The American Heart Association Scientific Sessions – Chicago, IL (November 2010)

• Does the Timing of PPI Dosing Influence the Antiplatelet Effect of Clopidogrel? Results of the SPACING Study

The American Pain Society’s 29th Annual Scientific Meeting – Baltimore, MD (May 2010)

• Analgesic Doses of Aspirin Cause Significant Upper Gastrointestinal Damage: PA65020, a New Combination of Enteric-Coated Aspirin & Immediate-Release Omeprazole Significantly Reduces the Incidence of Gastroduodenal Ulcers

The American College of Gastroenterology Annual Scientific Meeting – San Diego, CA (October 2009)

• Incidence of Gastroduodenal Ulcers is Significantly Reduced When Analgesic Doses of Aspirin are Administered as PA65020, A Novel Combination of Enteric-Coated Aspirin (EC-ASA) and Immediate-Release (IR) Omeprazole

International Society on Thrombosis and Haemostasis – Boston, MA (July 2009)

• PA32520 (Single-tablet of Immediate-Release Omeprazole 20 mg + Enteric-Coated Aspirin 325 mg): Safer Aspirin Therapy with Greater Thromboxane Suppression

International Stroke Conference – San Diego, CA (February 2009)

• Efficacy and Safety of PA, a Novel Combination of Enteric-Coated Aspirin and Immediate-Release Omeprazole

The American Heart Association Scientific Sessions – New Orleans, LA (November 2008)

• PA32520 (Single-Tablet of Enteric-Coated Aspirin 325 mg + Immediate-Release Omeprazole 20 mg): Aspirin Therapy Combining Greater Thromboxane Suppression and Lower Upper Gastrointestinal Damage

Arthritis (PN/VIMOVO)

The European League Against Rheumatism 2010 Congress – Rome, Italy (June 2010)

• Is age a predictor of endoscopic gastric ulcers in patients taking chronic NSAIDs? A pooled analysis including 854 patients from two Phase 3 studies comparing PN 400 and enteric-coated naproxen

The American College of Gastroenterology Annual Scientific Meeting – San Diego, CA (October 2009)

• PN 400 Significantly Improves Upper Gastrointestinal Tolerability Compared with Enteric-Coated Naproxen Alone in Patients Requiring Chronic NSAID Therapy: Results from Two Prospective, Randomized, Controlled Trials

2009 American College of Rheumatology/ARHP Annual Scientific Meeting – Philadelphia, PA (October 2009)

• PN 400 Significantly Reduces the Incidence of Gastric Ulcers Compared with Enteric-Coated Naproxen in Patients Requiring Chronic NSAID Therapy Regardless of Low-Dose Aspirin Use: Results from Two Prospective, Randomized Controlled Trials

Digestive Disease Week – Chicago, IL (June 2009)

• Gastric acid suppression with PN400, a single-tablet, multilayer, fixed-dose formulation combining an immediate-release esomeprazole layer and an enteric-coated naproxen core
• Pharmacokinetics of naproxen and esomeprazole in PN400, a single-tablet, multilayer formulation of enteric-coated naproxen coupled with immediate-release esomeprazole

European League Against Rheumatism – Paris (June 2008)

• A novel, single-tablet formulation that delivers immediate-release omeprazole followed by enteric-coated (EC) naproxen significantly reduces the incidence of gastric ulcers compared with EC naproxen alone: results of a prospective, randomised, double-blind, 6-month study including patients with OA and RA

Digestive Disease Week – San Diego, CA (May 2008)

• A single tablet multilayer formulation of enteric-coated naproxen coupled with non-enteric-coated omeprazole is associated with a significantly reduced incidence of gastric ulcers vs enteric-coated naproxen: a prospective, randomized, double-blind study

First Albany Pain Conference (March 2006)

• Podium Presentation: Designing a Safer NSAID

American College of Gastroenterology Annual Meeting, Honolulu, Hawaii (November 2005)

• Podium Presentation: PN 100-103

Migraine (MT 400/Treximet)

Migraine Trust Abstracts – London (September 2006)

• Optimizing Efficacy in the Acute Treatment of Migraine: Evaluation of the Clinical Benefits of Treatment Paradigm and Combination Therapy (Fixed Single-Tablet Formulation of Sumatriptan 85mg RT Technology™ and Naproxen Sodium 500mg, SumaRT/Nap)
• Early Sumatriptan Pharmacokinetics Following a Sumatriptan 100mg RT Technology™ Tablet and a Fixed Single-Tablet Formulation of Sumatriptan 85mg RT Technology™ and 500 MG Naproxen Sodium
• Consistent Efficacy and Tolerability Across Four Migraine Attacks of a Fixed Single-Table Formulation of Sumatriptan 85mg RT Technology™ and Naproxen Sodium 500mg (SumaRT/Nap)

AHS Meeting – Los Angeles, CA (June 2006)

• A New Migraine Therapy: Efficacy and Tolerability of a Fixed Single-Tablet Formulation of Sumatriptan RT Technology™ and Naproxen Sodium in the Early Intervention Paradigm

Headache Magazine (September 2005) article by Dr. Timothy R. Smith

• Research Submission: Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine

Poster Presentations at the 2005 AHS 47th Annual Scientific Meeting (June 2005)

• Evidence For A Role of Dopamine In Migraine?
• Pharmacokinetic Profile Of Sumatriptan RT Technology and Naproxem Sodium – New Single-tablet Formulation

Poster Presentations at the XI Congress of the International Headache Society (September 2003)

• Time Course of Symptom Relief with Various Anti-migraine Therapies

Poster Presentations at the 2003 AHS 45th Annual Scientific Meeting (June 2003)

• Defining and Analyzing Meaningful Relief in Clinical Trials of Acute Migraine Headache

Poster Presentations at the 2003 American College of Clinical Pharmacy Scientific Meeting (November 2003)

• Over-encapsulated Imitrex 50 mg Tablets are Bioequivalent to Marketed Imitrex 50 mg Tablets